Executive Vice President, Oncology R&D, AstraZeneca
Appears in 2 stories
Defending the camizestrant filing before ODAC
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated May 31
Leading AstraZeneca's oncology pipeline; Enhertu is the company's top-selling cancer drug
The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.
Updated May 18
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
